Latest news for Premier Miton Group (OTC:PASMF) Stock

Premier Miton Group PLC is focused on delivering good investment outcomes for investors through relevant products and active management. The company's investment capabilities are designed to meet the investment objectives and preferences of different clients and cover a broad range of multi-asset, equity, absolute return, and fixed income investments. Its only operating segment being asset management. Majority of revenue is generated from Management fees. Revenue is derived from the UK and Channel Islands.

PREMIER ASSET MGMT GROUP by Premier Asset Management Group

Premier Miton Group PLC

On the back of her highly successful beauty brand, popular singer and actress&nbsp;Selena Gomez&nbsp;has joined the ranks of the youngest self-made female billionaires in the U.S.
What Happened: On Friday, Gomez&#8217;s net worth was estimated to be around $1.3 billion, which was largely attributed to her makeup line, Rare Beauty Brands Inc., <a href="https://www.bloomberg.com/news/articles/2024-09-06/selena-gomez-is-a-billionaire-after-rare-beauty-success-exclusive">reported</a> Bloomberg.
The 32-year-old &#8220;Same Old Love,&#8221; singer&#8217;s wealth also comes from her brand partnerships, acting deals, and her mental-health startup, Wondermind.
See Also:&nbsp;<a href="https://www.benzinga.com/general/biotech/24/09/40742928/apple-watch-saves-life-of-pregnant-woman-and-her-baby-that-information-is-like-gold?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Watch Saves Life Of Pregnant Woman And Her Baby: &#8216;That Information Is Like Gold&#8217;</a>
According to the report, Gomez has diversified her income sources &#8211; this is unlike her close friend Taylor Swift, who has accumulated her wealth primarily through her music.
&#8220;Selena is not just a pop star,&#8221; said Stacy Jones, CEO of Hollywood Branded, according to the report. &#8220;She's a multifaceted businesswoman with diverse income streams contributing to her impressive net worth.&#8221;
&#8220;You've got a real role model of how a celebrity can use their influence and expertise to both do good and create good business,&#8221; stated Brent Saunders, CEO of Bausch + Lomb Corp. and an investor in Gomez's Wondermind startup. &#8220;Selena epitomizes that,&#8221; she added, according to the report.
Why It Matters: Gomez began her career at a young age, appearing on&nbsp;Barney &amp; Friends&nbsp;before rising to fame as Alex Russo on Disney&#8217;s&nbsp;Wizards of Waverly Place.
After playing the role of a wizard in the show she led a successful music career with hits as the frontwoman of Selena Gomez &amp; the Scene, and later as a solo artist.
However, her path was not without obstacles. The singer has openly battled health issues, including a lupus diagnosis, which led to a kidney transplant in 2017. 
She has also faced mental health struggles. She has previously revealed her bipolar disorder diagnosis.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40678873/cathie-wood-congratulates-elon-musk-on-xai-milestone-after-ai-firm-brings-100k-nvidia-gpu-colossus-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Congratulates Elon Musk On xAI Milestone After AI Firm Brings 100K Nvidia GPU Colossus Cluster Online In Just 122 Days: &#8216;Many Big Announcements Ahead&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Entertainment

News

Media

Selena Gomez Enters Billionaire Club, Thanks To Rare Beauty's Triumph

Boeing Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) troubled space capsule, Starliner, has returned to Earth without any crew after a test flight <a href="https://www.benzinga.com/topic/starliner">fraught with technical issues</a> and delays.
What Happened: The Starliner departed the International Space Station at 6:04 p.m. Friday New York time and landed in White Sands, New Mexico, after a six-hour flight.
The mission has garnered global attention due to numerous technical problems that led NASA to extend the stays of astronauts Barry "Butch" Wilmore and Sunita "Suni" Williams.
Originally scheduled to return in the Starliner, Williams and Wilmore will now remain on the ISS until early 2025, when a SpaceX craft will bring them back. NASA deemed it too risky for astronauts to return in the Boeing vehicle due to ongoing thruster issues.
NASA officials monitored the thrusters&#8217; performance during the return to evaluate their capability.
Despite the concerns, NASA&#8217;s Steve Stich expressed confidence in the vehicle during a press conference. However, the root cause of the issues remains unclear, and NASA&#8217;s future plans for Starliner are still undecided.
See Also: <a href="https://www.benzinga.com/24/09/40720928/elon-musk-to-unveil-reversible-seats-in-tesla-robotaxis-no-longer-a-driver-seat-in-the-vehicle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk To Unveil Reversible Seats In Tesla Robotaxis? &#8216;No Longer A Driver Seat In The Vehicle&#8217;</a>
Why It Matters: The return of Boeing&#8217;s Starliner without crew underscores a series of setbacks for the aerospace giant. On Sept. 4, the crew aboard the ISS <a href="https://www.benzinga.com/news/24/09/40700719/boeing-starliner-return-sunita-williams-and-butch-wilmore-prepare-spacecraft-for-uncrewed-journey-ba">prepared the Starliner</a> for its uncrewed journey back to Earth.
Earlier, on Sept. 2, astronaut Wilmore <a href="https://www.benzinga.com/news/24/09/40671005/boeing-starliner-speakers-make-a-kind-of-pulsing-noise-almost-like-a-sonar-ping-strange-sound-report">reported hearing strange sonar-like sounds</a> from a speaker inside the Starliner, baffling NASA officials in Houston.
Due to these ongoing issues, NASA had to <a href="https://www.benzinga.com/news/24/08/40665221/nasa-revamps-spacexs-crew-9-lineup-to-make-room-for-astronauts-stranded-at-iss-due-to-boeings-starli">revamp its SpaceX Crew-9 lineup</a> on Aug. 30 to make room for the astronauts stranded at the ISS. Only two astronauts will launch on NASA's upcoming SpaceX Crew-9 mission instead of four.
Adding to the tension, SpaceX CEO Elon Musk <a href="https://www.benzinga.com/news/24/08/40594834/spacex-ceo-elon-musk-takes-another-dig-at-boeing-for-failing-to-return-astronauts-on-starliner-ride">took another dig</a> at Boeing, highlighting the company&#8217;s failure to return astronauts on the Starliner.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40546859/boeings-former-ceo-dennis-muilenburg-said-in-2017-his-company-will-beat-elon-musk-to-mars-7-years-la">Boeing&#8217;s Former CEO Dennis Muilenburg Said In 2017 His Company Will Beat Elon Musk To Mars. 7 Years Later, It Has Been Forced To Abandon NASA Astronauts At ISS, Who Will Now Be Rescued By SpaceX</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: NASA

SPACE

Tech

Boeing Starliner Returns To Earth Without Sunita Williams And Butch Wilmore, Lands In New Mexico After 6-Hour Flight

NBA legend Shaquille O&#8217;Neal, also known as Shaq, <a href="https://www.benzinga.com/general/entertainment/24/08/40413674/nba-legend-shaq-missed-his-tesla-cybertruck-so-much-instead-of-shipping-it-from-vegas-to-at">showed off his new</a> Tesla Inc. Cybertruck featuring a widebody carbon fiber design, which is the first of its kind in the world.
What Happened: Shaq&#8217;s latest acquisition is a customized Tesla Cybertruck, crafted by Effortless Motors. The vehicle, dubbed the &#8220;Cyberbeast,&#8221; boasts a widebody kit and carbon fiber construction, making it both lighter and visually striking.
The inspiration for this unique Cybertruck came from LeBron James. After learning about LeBron&#8217;s custom Cybertruck from Effortless Motors, Shaq saw an opportunity to create a vehicle that suited his style and size.
Effortless Motors delivered the Cyberbeast to Shaq&#8217;s home in Las Vegas. The vehicle features massive 26-inch rims and a black-on-black color scheme, adding to its commanding road presence.
Tesla CEO Elon Musk was left impressed with Shaq's new Cybertruck. He had a one-word reaction to it: "nice."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nice
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1832238280709939293?ref_src=twsrc%5Etfw">September 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/09/40701340/tesla-introduces-winter-package-for-cybertruck-priced-at-3k-ahead-of-the-mercury-drop?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Introduces Winter Package For Cybertruck Priced At $3K Ahead Of The Mercury Drop</a>
While performance specs for this custom Cybertruck are not detailed, Shaq&#8217;s previous tri-motor Cybertruck could achieve 845 hp and accelerate from 0 to 60 mph in 2.6 seconds.
Shaq&#8217;s garage is already known for its impressive collection of vehicles that match his larger-than-life personality. The addition of this futuristic and spacious Tesla Cybertruck further enhances his legendary lineup.
Why It Matters: Last month, it was reported that Shaq <a href="https://www.benzinga.com/general/entertainment/24/08/40413674/nba-legend-shaq-missed-his-tesla-cybertruck-so-much-instead-of-shipping-it-from-vegas-to-at">chose to purchase another Cybertruck</a> instead of shipping his existing one from Las Vegas to Atlanta.
The unveiling of Shaq&#8217;s custom Cybertruck is part of a broader trend among celebrities who are gravitating toward Tesla&#8217;s futuristic vehicles. Musk has publicly praised the <a href="https://www.benzinga.com/general/entertainment/24/02/37412516/they-clearly-have-great-taste-tesla-ceo-elon-musk-thrilled-by-growing-list-of-celebs-buying">growing list of celebrities</a> purchasing Cybertrucks, highlighting their appeal without any discounts or paid promotions.
In March, Steve Aoki and Big Sean were <a href="https://www.benzinga.com/general/entertainment/24/03/37852639/tesla-cybertruck-the-new-celebrity-fashion-accessory-steve-aoki-big-sean-latest-to-own-ev">among the latest celebrities</a> to join the Cybertruck craze, further cementing its status as a must-have accessory in the entertainment world.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40747427/tesla-won-some-brownie-point-by-not-doing-anything-wrong-like-gm-volkswagen-says-industry-watche?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Won Some Brownie Points By Not Doing Anything Wrong Like GM, Volkswagen, Says Industry Watcher</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Sports

NBA Legend Shaq Shows Off His New Widebody Carbon Fiber Tesla Cybertruck: Elon Musk Has A One Word Reaction

The <a href="https://www.benzinga.com/topic/2024-presidential-election">presidential race is heating</a> up in Florida and Texas, with&nbsp;former President Donald Trump and Vice&nbsp;President Kamala Harris running neck and neck.
What Happened: A <a href="https://thehill.com/homenews/campaign/4865482-trump-harris-florida-texas-poll/">poll</a> released on Friday by&nbsp;Emerson College Polling/The Hill&nbsp;reveals a tight race in both states,&nbsp;within the margin of error. Trump leads Harris by 5 points in Florida and 4 points in Texas, aligning with the trend of a tightening race in these states.
Winning either Florida, a state Democrats&nbsp;carried in 2008 and 2012, or Texas, a state Democrats hope to turn blue, would be a significant challenge for Harris.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40754141/trumps-attorney-general-william-barr-accuses-biden-harris-admin-of-politicizing-cannabis-legaliz?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Attorney General William Barr Accuses Biden-Harris Admin Of Politicizing Cannabis Legalization</a>
The poll also shows&nbsp;a significant gender gap, with&nbsp;Trump leading among men in Texas by 18 points and in Florida by 12 points. Harris leads among women in Texas by 8 points and in Florida by 2 points.
The poll was conducted from&nbsp;Sept. 3-5 among 815 likely&nbsp;voters in Florida and 845&nbsp;likely voters in Texas. The&nbsp;margin of error for Florida&nbsp;was 3.4 percentage points, and&nbsp;for Texas, it was 3.3 percentage points.
Why It Matters: Earlier this week, it was reported that Vice President&nbsp;Harris has significantly outpaced Trump in <a href="https://www.benzinga.com/news/24/09/40750154/harris-vs-trump-vice-president-outpaces-gop-rival-in-august-fundraising-as-presidential-race-heats-u">fundraising for August</a>, potentially boosting her campaign efforts.
In August, Harris's presidential campaign and the Democratic Party raised $361 million, leaving her with $404 million in cash at the start of September. Trump's campaign and the Republican Party raised $130 million in August, ending the month with $295 million in cash.
Meanwhile, on Friday, Trump&#8217;s sentencing for the hush money trial was <a href="https://www.benzinga.com/general/politics/24/09/40754802/trump-hush-money-sentencing-will-now-take-place-after-2024-election-to-avoid-any-appearance-to-a">postponed until after the election</a>.
On the same day, former Vice President Dick Cheney <a href="https://www.benzinga.com/news/24/09/40758275/former-vice-president-dick-cheney-backs-kamala-harris-says-trump-is-a-greater-threat-to-our-republic">publicly backed Harris</a>, stating that Trump is a &#8220;greater threat to our republic&#8221; than any other individual.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40686379/trump-vs-harris-veteran-pollster-nate-silver-says-vice-president-slight-underdog-to-win-the-white-ho?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Vs. Harris: Veteran Pollster Nate Silver Says Vice President ‘Slight Underdog To Win The White House&#8217; Due To 3 Factors But This ‘Disruptive Event&#8217; Could Turn Things Around</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Politics

Trump Vs. Harris: Latest Poll Shows The Two Presidential Candidates Are Neck And Neck In These Two States

Tech <a href="https://www.benzinga.com/topic/bill-gates">billionaire and philanthropist</a> Bill Gates has revealed a comprehensive strategy aimed at eradicating malaria, a disease that has plagued humanity for centuries. Gates&#8217; plan includes several groundbreaking technologies and innovations.
What Happened: Last month, in a post <a href="https://www.gatesnotes.com/Great-news-for-mosquito-haters">on</a> his blog, Gates underscored several potential breakthroughs that could help humanity overcome its ancient foe once and for all.
This is important, given that estimates suggest that malaria has wiped out half of humanity in its existence. According <a href="https://www.nature.com/articles/news021001-6">to</a> a Nature article, malaria has killed 50-60 billion humans, nearly half of the <a href="https://www.prb.org/articles/how-many-people-have-ever-lived-on-earth/">estimated</a> 117 billion humans born so far.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06233301/Anopheles-mosquito-malaria-1-1024x576.jpg" alt="" class="wp-image-535604" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06233301/Anopheles-mosquito-malaria-1-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06233301/Anopheles-mosquito-malaria-1-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06233301/Anopheles-mosquito-malaria-1-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06233301/Anopheles-mosquito-malaria-1-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06233301/Anopheles-mosquito-malaria-1.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Anopheles mosquito &#x7C; Photo courtesy: Wikimedia</figcaption></figure>
For context, the current human population of around 8 billion is nearly seven times lower than the humans estimated to have been killed by malaria so far.
See Also: <a href="https://www.benzinga.com/news/24/08/40594137/heres-what-nvidias-jensen-huang-had-to-say-about-amd-ceo-and-his-cousin-lisa-su">Here's What Nvidia's Jensen Huang Had To Say About AMD CEO And His Cousin Lisa Su</a>
Malaria Vaccines: Two first-generation malaria vaccines have been approved, but they have limitations, especially in terms of long-lasting protection and transmission prevention. Researchers are now focusing on next-generation vaccines that could work for all ages, require fewer doses, and significantly reduce transmission.
Gene Drive Technology: Gene drive technology is another promising approach. Scientists in London are editing the doublesex gene in female Anopheles mosquitoes to make their proboscis too flimsy to bite humans, potentially reducing malaria transmission.
Injectable Prevention Tools: Injectable prevention tools, including long-acting injectable medicines (LAIs), are being explored. These could provide months of protection and are particularly useful in areas with seasonal malaria transmission or limited healthcare access. Late-stage LAI trials are expected to yield results by 2028.
Single Encounter Radical Cures: New treatments like single encounter radical cures (SERCs) aim to cure malaria in one dose and make patients temporarily toxic to mosquitoes. A new SERC combination is in late-stage trials and could be approved by 2026.
Attractive Targeted Sugar Baits: Attractive targeted sugar baits (ATSBs) are being improved to exploit mosquitoes&#8217; need for sugar, offering a sweet treat laced with insecticide. Field testing of these prototypes will soon be underway.
Drones And AI: Technologies like drones and AI are helping identify and attack mosquito breeding sites more effectively, aiding in larval source management. This tech-enabled approach is particularly useful in urban areas.
Gates emphasizes that while scientific advancements are crucial, financial and political commitment is also necessary to eradicate malaria. He calls for global attention and funding to make this dream a reality.
Why It Matters: Science journal Nature described malaria as one of the deadliest diseases known to mankind, highlighting the need for innovative solutions to combat this ancient scourge.
Previously, Gates also shared his excitement about <a href="https://www.benzinga.com/news/23/12/36322815/bill-gates-reveals-five-cutting-edge-ai-innovations-he-is-excited-about">five groundbreaking AI innovations</a> that could revolutionize healthcare. These innovations include AI-driven tools for disease prevention and treatment, which are integral to his malaria eradication plan.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40624456/dean-of-valuation-aswath-damodaran-shares-3-ways-to-beat-the-bot-and-safeguard-your-job-from-ai">Dean Of Valuation Aswath Damodaran Shares 3 Ways To Beat The Bot And Safeguard Your Job From AI</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Biotech

Health Care

General

Malaria May Have Killed Half Of Humans Throughout History. Now, Bill Gates Has A Breakthrough Plan That Could End It For Good

Former Vice President Dick Cheney has announced his intention to vote for Democratic presidential candidate Kamala Harris in the <a href="https://www.benzinga.com/topic/2024-presidential-election">forthcoming presidential elections</a>.
What Happened: On Friday, Cheney, who served under former President George W. Bush, said, &#8220;In our nation&#8217;s 248-year history, there has never been an individual who is a greater threat to our republic than Donald Trump,&#8221; reported Reuters.
&#8220;As citizens, we each have a duty to put country above partisanship to defend our Constitution. That is why I will be casting my vote for Vice President Kamala Harris,&#8221; the former Republican added. He also said Trump &#8220;can never be trusted with power again.&#8221;
In response, the Harris campaign announced that the Cheneys had aligned themselves with a growing movement of Republicans prioritizing country over party by endorsing Harris.
Cheney&#8217;s decision follows a similar announcement made by his daughter, Liz Cheney, earlier this week, the report noted.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/40679223/mark-cuban-explains-why-despite-getting-a-lot-of-flak-from-elon-musk-and-others-he-continues-to-post?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Explains Why, Despite Getting A Lot Of Flak From Elon Musk And Others, He Continues To Post On X: ‘Don't Want to Be Where Everyone Agrees with Me'</a>
Meanwhile, former President Donald Trump labeled the Cheneys as &#8220;irrelevant RINO&#8221; in a social media post on Friday, which means &#8220;Republicans in Name Only.&#8221;
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06220209/Screenshot-2024-09-07-at-7.32.02%E2%80%AFAM-1024x682.png" alt="" class="wp-image-535573" style="width:578px;height:auto" /><figcaption class="wp-element-caption">Screenshot of Donald Trump&#8217;s post on Truth Social</figcaption></figure>
Why It Matters: A <a href="https://www.benzinga.com/news/24/09/40722406/trump-vs-harris-poll-shows-former-president-leading-among-veterans-and-active-service-members-but-su">poll conducted last month</a> showed Trump leading among veterans and active service members, although his support has declined since 2016.
When questioned about their shift in support, 53% of those who previously voted for him at least once attributed their change to his remarks, attitudes, and policies concerning veterans and service members.
Earlier this week, former White House Communications Director Anthony Scaramucci&nbsp;said&nbsp;that Trump was shaken by Harris, but <a href="https://www.benzinga.com/news/24/09/40727647/trump-shaken-by-kamala-harris-says-anthony-scaramucci-but-calls-him-an-adaptive-guy-hell-find-the-ri">also noted his adaptability</a>.
&#8220;You've had this great demographic recirculation, so when he calls her stupid and he says she turned black and all this sort of nonsense, baby boomers were conditioned to deal with that, but the generation Zs, they don't like it at all,&#8221; he said.
Meanwhile, on Friday, it was announced that Trump&#8217;s sentencing for the hush money trial will&nbsp;occur&nbsp;after the 2024 presidential election, to <a href="https://www.benzinga.com/general/politics/24/09/40754802/trump-hush-money-sentencing-will-now-take-place-after-2024-election-to-avoid-any-appearance-to-a">avoid influencing the election outcome</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40686379/trump-vs-harris-veteran-pollster-nate-silver-says-vice-president-slight-underdog-to-win-the-white-ho?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Vs. Harris: Veteran Pollster Nate Silver Says Vice President ‘Slight Underdog To Win The White House' Due To 3 Factors But This ‘Disruptive Event' Could Turn Things Around</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

Former Vice President Dick Cheney Backs Kamala Harris, Says Trump Is A 'Greater Threat To Our Republic' Than Any Other Individual

PRFX

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

WIIM

DELL

Dell Technologies shares are trading higher amid its addition to the S&P 500 index.

PLTR

Palantir Technologies shares are trading higher amid its addition to the S&P 500 index.

<h3 class="wp-block-heading">First Weed Shop In North Carolina To Open This Weekend</h3>
The first legal recreational cannabis store in North Carolina is slated to open its doors to customers on Saturday, Sept. 7 at 91 Bingo Loop Road in Cherokee, Swain County, <a href="https://www.citizen-times.com/story/news/local/2024/09/03/north-carolinas-1st-recreational-marijuana-dispensary-set-to-open/75010685007/">reported</a> The Asheville Citizen-Times.
Great Smoky Cannabis Co., an Eastern Band of Cherokee Indians (ECBI) medical marijuana <a href="https://www.benzinga.com/markets/cannabis/24/08/40134964/north-carolinas-first-and-only-recreational-marijuana-shop-opening-soon-thanks-to-eastern-band-o">announced this summer</a> that recreational cannabis was available to adult members of the ECBI and other federally recognized Native American tribes. Now the store opening celebration is about to take place.
 ECBI&#8217;s members said yes to <a href="https://www.benzinga.com/markets/cannabis/23/09/34358061/cherokee-tribe-votes-to-legalize-marijuana-in-north-carolina-despite-gop-congressmans-threats">recreational cannabis on&nbsp;a Sept. 7 referendum in 2023.</a>
<h3 class="wp-block-heading">D.C. MMJ Dispensaries Are At Risk Of Shutting Down, Here's Why</h3>
In Washington D.C. owners of licensed medical cannabis dispensaries say their businesses are at stake as they are affected by the so-called I-71 weed shops as well as the relatively nascent, but burgeoning Maryland cannabis market, reported Axios.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
That said, the District Is now expected to act on &#8220;gray area&#8221; I-71 shops. Earlier this year, the D.C. Council approved an emergency measure to give city officials the authority to impose penalties on unlicensed marijuana gifting shops not operating under <a href="https://www.benzinga.com/markets/cannabis/24/01/36597430/new-emergency-law-empowers-authorities-to-crack-down-on-cannabis-gifting-shops-in-d-c">the city&#8217;s medical cannabis program.</a> Since then, &nbsp;some have decided to go legit. The Alcoholic Beverage and Cannabis Administration (ABCA) published a list of businesses shortly, looking to transition from D.C.&#8217;s I-71 gifting market to legal medical dispensaries. Out of 76 submitted applications, a total of 26 D.C. unlicensed retailers have been awarded placards, including 12 social equity <a href="https://www.benzinga.com/markets/cannabis/24/02/37220237/dcs-weed-gifting-goes-legit-nebraskans-want-medical-marijuana-legalized-and-more-cannabis-regs">applicants and 14 standard applicants.</a>
Five legal dispensaries went out of business in the past two years, according to Grace Hyde, a director at District Cannabis and co-chair of the Regulated Cannabis Association of DC. One of the reasons are higher prices of products sold in licensed shops, as the product is regulated and sourced from D.C. cultivators.
Hyde urged Mayor Muriel Bowser to tackle the issue of the I-71 shops. &#8220;I would say the industry has — without enforcement — 60 days before we start to collapse,&#8221; she said. &#8220;Our business has not broken even in any single month in 2024.&#8221;
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39297599/dc-residents-fight-against-cannabis-dispensaries-near-schools-is-there-a-real-danger-for-childre">DC Residents Fight Against Cannabis Dispensaries Near Schools: Is There A Real Danger For Children?</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06111232/ccc-oct-24-banner__1_-12.gif" alt="" class="wp-image-534890" /></a></figure>
<h3 class="wp-block-heading">Florida Medical Marijuana Giant Ramps Up National Retail Footprint And Other Stores That Launched Cannabis Sales</h3>
Meanwhile, Trulieve Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) has been ramping up its presence nationwide.
In Florida, the medical cannabis giant launched sales at a new medical cannabis dispensary in Orlando. Located at 6655 S Semoran Blvd, the store started serving patients in late August.
On Friday, the Tallahassee-based company held ribbon-cutting celebrations at three medical cannabis dispensaries including stores in Miramar Beach, Niceville and Tampa, while the Cocoa shop is slated to open on Saturday, Sept. 7.
The same day, Trulieve will launch sales at a new medical cannabis dispensary in Clearwater as well.
The company also relocated its dispensary in Tucson, Arizona. The new Menlo Park location at 1010 S Freeway #130 will host a grand opening celebration starting on Friday, Sept. 13.
Texas Original medical cannabis provider wrapped up last month by announcing the opening of a pickup location in the Katy area. Located at 810 S. Highway 6 #101, the Katy site offers Texas Original's full suite of medical cannabis products to qualifying patients registered under the state's Compassionate Use Program (CUP).
Canadian cannabis retail giant High Tide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/HITI#TSXV">HITI</a>) (FSE: 2LYA) announced on Thursday that its Canna Cabana retail cannabis store located at 389 Main Street, Lucan, Ontario will begin selling recreational cannabis products and consumption accessories for adult use on Friday, Sept. 6. This opening will mark the company&#8217;s 183rd Canna Cabana branded retail cannabis location in Canada, the 69th in the province. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40528453/heres-where-to-buy-legal-weed-khalifa-kushs-store-in-las-vegas-west-hollywoods-lgbtq-owned-canna">Here&#8217;s Where To Buy Legal Weed: Khalifa Kush&#8217;s Store In Las Vegas, West Hollywood&#8217;s LGBTQ+ Owned Cannabis Dispensary And More</a></li>
</ul>

Cannabis

Entrepreneurship

CSE:TRUL

HITI

TCNNF

TRUL

TSXV:HITI

First Weed Shop In North Carolina, Why Are D.C. Medical Marijuana Shops Closing Down? More New Places To Buy Legal Cannabis

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20240906-1474143/1474143_septembershuffle546.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20240906-1474143/1474143_septembershuffle546.pdf</a>
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&amp;P 500; Others to Join S&amp;P MidCap 400 and S&amp;P SmallCap 600
&nbsp;
NEW YORK, September 6, 2024: S&amp;P Dow Jones Indices (&quot;S&amp;P DJI&quot;) will make the following changes to the S&amp;P 500, S&amp;P MidCap 400, and S&amp;P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&amp;P 500 are more representative of the large-cap market space, all companies being added to the S&amp;P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&amp;P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S&amp;P SmallCap 600 are no longer representative of the small-cap market space. 
&nbsp;
Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), and S&amp;P MidCap 400 constituent Erie Indemnity Co. (NASD:ERIE) will replace American Airlines Group Inc. (NASD:AAL), Etsy Inc. (NASD:ETSY) and Bio-Rad Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) in the S&amp;P 500, respectively. American Airline Group will replace TEGNA Inc.&nbsp;in the S&amp;P MidCap 400, and TEGNA will replace Designer Brands Inc. in the S&amp;P SmallCap 600. Etsy will replace Haverty Furniture Companies Inc.&nbsp;in the S&amp;P SmallCap 600. Bio-Rad Laboratories will replace Erie Indemnity in the S&amp;P MidCap 400.

Small Cap

Markets

ERIE

ETSY

Palantir Technologies, Dell Technologies, And S&P MidCap 400 Constituent Erie Indemnity Co. Set To Join S&P 500; Will Replace American Airlines Group, Etsy And Bio-Rad Laboratories

Editor&#8217;s note: This story has been updated to include reactions from California hemp industry stakeholders.
California Governor Gavin Newsom made a sudden move on Friday, proposing emergency regulations that would completely ban THC, the intoxicating compound found in cannabis, from all hemp products in the state. 
The proposed <a href="https://www.cdph.ca.gov/Programs/OLS/Pages/DPH-24-005E-Emergency-Regulations-for-Industrial-Hemp.aspx">regulations</a>, released by the California Department of Public Health, would require that all industrial hemp food, beverage and dietary supplements produced for human consumption would need to be free of THC and other cannabinoids, reported <a class="" href="https://thehill.com/homenews/state-watch/4865744-california-thc-hemp-regulations-proposal/">the Hill</a>.
Hemp products, which are essentially unregulated, can be easily bought online or at places like gas stations or convenience stores throughout the state. Newsom said in a <a href="https://www.gov.ca.gov/2024/09/06/governor-newsom-issues-regulations-to-protect-kids-from-dangerous-and-intoxicating-hemp-products/">statement</a> that the emergency rules were necessary to protect children.
"We will not sit on our hands as drug peddlers target our children with dangerous and unregulated hemp products containing THC at our retail stores. We're taking action to close loopholes and increase enforcement to prevent children from accessing these dangerous hemp and cannabis products," Newsom said.
In addition to requiring that all hemp products in California have "no detectable amount of total THC," the governor and health officials want customers be over 21 to purchase the products. The rules still need the approval of the California Office of Administrative Law before they go into effect, according to the outlet. 
<h2 class="wp-block-heading">Industry Stakeholders Quick To Respond</h2>
&#8220;Today's &#8217;emergency action&#8217; by Governor Newsom is a betrayal of California hemp farmers, small businesses, and adult consumers,&#8221; the Hemp Roudtable told Benzinga. &#8220;After having supported AB 45, which created a sound regulatory framework for the manufacture and sale of hemp products, Newsom's Administration fell on the job and failed to take any steps to enforce it.&#8221;
The Roundtable took the governor to task for not establishing policies to keep intoxicating products away from children rather than punishing the entire industry. &#8220;And in the middle of massive California budget deficits, he is unnecessarily throwing away nearly a quarter billion dollars in tax revenue from legitimate small businesses.&#8221; 
The Hemp Roundtable vowed to explore all legal options in the coming days &#8220;with California hemp farmers and businesses that comprise the multi-billion-dollar industry that this action would destroy.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38225285/in-just-3-months-california-seized-over-53m-in-illegal-cannabis-gov-newsom-announces-more-aggres">In Just 3 Months California Seized Over $53M In Illegal Cannabis, Gov. Newsom Announces More &#8216;Aggressive Actions&#8217;</a>
Case Mandel, CEO of <a href="https://www.benzinga.com/markets/cannabis/21/11/23957010/herbl-to-distribute-cannadips-new-thc-infused-pouches-in-california">Cannadips</a>, also spoke out. "This will destroy our business," Mandel told Benzinga. He explained that even though most Cannadips' products are THC-free, they come in packages of 15 servings, which would make them illegal under the new rules, which require packages be limited to just five servings. 
"This will also attack the full-spectrum CBD industry that has provided high-quality products that people rely on in the state of California," Mandel said. "We can understand passing laws that affect what can be sold in CA. What we don't understand is why they affect what can be manufactured and sold legally nationwide. We ask that Gavin Newsom wises up and looks for legislation that actually represents his objectives, not private interests." 
Read Gov. Newsom&#8217;s <a href="https://www.gov.ca.gov/2024/09/06/governor-newsom-issues-regulations-to-protect-kids-from-dangerous-and-intoxicating-hemp-products/">press release</a> for more details and <a href="https://www.cdph.ca.gov/Programs/OLS/Pages/DPH-24-005E-Emergency-Regulations-for-Industrial-Hemp.aspx">draft regulations</a>.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40638186/in-amsterdam-style-california-senate-moves-to-legalize-cannabis-farmers-markets-and-cafes">In Amsterdam Style, California Senate Moves To Legalize Cannabis Farmers Markets And Cafes</a></li>
</ul>
Photo: Benzinga edit with images by&nbsp;<a href="https://www.flickr.com/photos/usbr/53633995519/" target="_blank" rel="noreferrer noopener">Bureau of Reclamation</a>&nbsp;via Wikimedia Commons and&nbsp;<a href="https://unsplash.com/@robwarner?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Rob Warner</a>&nbsp;on&nbsp;<a href="https://unsplash.com/photos/green-and-brown-tree-under-blue-sky-wA-kp2Ad-To?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Unsplash</a>

Government

Regulations

Gov. Newsom's Total Ban On Hemp THC Could Crush California's Billion-Dollar Industry, Say Stakeholders (UPDATED)

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 10.9% on an annualized basis producing an average annual return of 23.53%. Currently, Vistra has a market capitalization of $25.29 billion. 
Buying $1000 In VST: If an investor had bought $1000 of VST stock 5 years ago, it would be worth $2,884.54 today based on a price of $73.60 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725658217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Vistra 5 Years Ago Would Be Worth Today

CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) has outperformed the market over the past 5 years by 2.67% on an annualized basis producing an average annual return of 15.3%. Currently, CBRE Group has a market capitalization of $34.80 billion. 
Buying $100 In CBRE: If an investor had bought $100 of CBRE stock 5 years ago, it would be worth $205.15 today based on a price of $113.55 for CBRE at the time of writing.
<h3>CBRE Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725658212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBRE

Here's How Much $100 Invested In CBRE Group 5 Years Ago Would Be Worth Today

Nelson Peltz Appointed Chairman Emeritus
DUBLIN, Ohio, Sept. 6, 2024 /PRNewswire/ -- The Wendy's Company (Nasdaq:&nbsp;WEN) today announced that its Board of Directors has appointed Arthur B. Winkleblack as non-executive Chairman of the Board. He succeeds Nelson Peltz, who has been named Chairman Emeritus in recognition of his long-time leadership, counsel, guidance and contributions to the Board and the Company.
Winkleblack has served as Lead Independent Director since October 2023 and has been a member of the Board since 2016. He also serves as Chairman of the Nominating and Corporate Governance Committee and as a member of the Audit Committee, where he is a past Chairman. Mr. Winkleblack has also been appointed as Chairman of the Executive Committee.
Peltz has served as non-executive Chairman of the Board since 2007. He is stepping down to devote more time to his other board commitments and Trian's future activities.

Management

The Wendy's Company Appoints Arthur Winkleblack As Non-Executive Chairman Of The Board, Succeeding Nelson Peltz, Who Has Been Named Chairman Emeritus

HII's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) Mission Technologies division announced today that Amy Boyette, a former Department of Energy (DOE) official with more than 30 years of experience in environmental management and National Nuclear Security Administration (NNSA) operations, has joined the company's Nuclear and Environmental Services (NES) business group as vice president of strategy and integration.
In her new role, Boyette will serve on the NES leadership team and focus on evaluating potential growth opportunities and providing strategic direction in a highly competitive domestic and international market space. She will also be responsible for building successful stakeholder relations in the communities in which the NES team and its joint venture partners operate.

Former DOE Official, Amy Boyette Joins HII's Nuclear Team As Vice President Of Strategy And Integration

Shopify Inc. ((NYSE, TSX:<a href="https://www.benzinga.com/stock/SHOP#TSX">SHOP</a>), announced today that Tobias Lütke, Shopify's Chief Executive Officer, has adopted an automatic securities disposition plan ("ASDP"), in accordance with securities laws and Shopify's internal policies, with sales of Class A Subordinate Voting Shares ("Class A Shares") under the plan eligible to commence on or after September 17, 2024. The Ontario Securities Commission issued a decision exempting Mr. Lütke from the prospectus requirements under Canadian securities legislation with respect to sales of Class A Shares under the ASDP. This announcement is made pursuant to the requirements of that decision. Mr. Lütke entered into automatic securities disposition plans under a similar exemption annually from 2017 to 2021.
The ASDP permits trades to be made in accordance with pre-arranged instructions given when Mr. Lütke was not in possession of material non-public information regarding Shopify. The ASDP provides for the sale of an aggregate of up to 2,564,964 Class A Shares and will terminate no later than December 31, 2025. All the Class A Shares that could potentially be sold under the ASDP are pursuant to vested options and restricted share units granted to Mr. Lütke as compensation for his services as Chief Executive Officer. The ASDP does not provide for the conversion of any multiple voting shares of the Company owned by Mr. Lütke.

Contracts

SHOP

Automatic Securities Disposition Plan Adopted By Shopify CEO Tobias Lütke; The ASDP Provides For The Sale Of An Aggregate Of Up To 2,564,964 Class A Shares And Will Terminate No Later Than December 31, 2025

Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Globant, presenting an average target of $222.07, a high estimate of $245.00, and a low estimate of $200.00. Witnessing a positive shift, the current average has risen by 4.41% from the previous average price target of $212.69.
<img src="https://www.benzinga.com/files/images/story/2024/1725656454_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Globant among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$237.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Bryan Keane</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$210.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$205.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Divya Goyal</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Leonardo Olmos</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$226.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Divya Goyal</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$238.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Globant. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Globant compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Globant's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Globant's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GLOB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Globant analyst ratings.</a>
<h2>All You Need to Know About Globant</h2>
Globant SA is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the U.S. and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
<h3>Globant's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Globant's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 18.08%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Globant's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.58% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Globant's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Globant's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.46% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Globant's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GLOB

A Glimpse Into The Expert Outlook On Globant Through 15 Analysts

In the last three months, 11 analysts have published ratings on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for UiPath, revealing an average target of $15.36, a high estimate of $18.00, and a low estimate of $14.00. This current average reflects an increase of 3.78% from the previous average price target of $14.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1725656441_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of UiPath among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to UiPath. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UiPath's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>Delving into UiPath's Background</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>A Deep Dive into UiPath's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: UiPath's revenue growth over a period of 3 months has been noteworthy. As of 30 April, 2024, the company achieved a revenue growth rate of approximately 15.72%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.58%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): UiPath's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.42%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): UiPath's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.99%, the company may face hurdles in achieving optimal financial performance.
Debt Management: UiPath's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PATH

Unveiling 11 Analyst Insights On UiPath

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Travere Therapeutics and provided 12-month price targets. The average target is $18.38, accompanied by a high estimate of $23.00 and a low estimate of $12.00. This upward trend is apparent, with the current average reflecting a 16.7% increase from the previous average price target of $15.75.
<img src="https://www.benzinga.com/files/images/story/2024/1725656434_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Travere Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carly Kenselaar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Allison Bratzel</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Travere Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Travere Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Travere Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Travere Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TVTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Travere Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Travere Therapeutics Better</h2>
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
<h3>Breaking Down Travere Therapeutics's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Travere Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 68.08%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Travere Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -130.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Travere Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -157.84%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Travere Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.59%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Travere Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 26.62, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Comments

Premier Miton Group

News

Latest news for Premier Miton Group (OTC:PASMF) Stock